ロード中...
Novel Humanitarian Aid Program: The Glivec International Patient Assistance Program—Lessons Learned From Providing Access to Breakthrough Targeted Oncology Treatment in Low- and Middle-Income Countries
Imatinib was the first targeted therapy approved for the treatment of cancer. With its approval, it was immediately clear to Novartis that this breakthrough therapy would require an innovative approach to worldwide access, with special consideration of low- and middle-income countries. Lack of gover...
保存先:
| 出版年: | J Glob Oncol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Clinical Oncology
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5551649/ https://ncbi.nlm.nih.gov/pubmed/28804770 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JGO.2015.000570 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|